BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Meda AB (MEDA-A.ST) Snags U.S. Respiratory Company Acton Pharmaceuticals, Inc. for Up to $200 Million


8/30/2013 6:46:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Acton Pharmaceuticals, Inc. to Be Acquired by Meda for Up to $200 Million

Acton Pharmaceuticals, Inc., a specialty respiratory pharmaceutical company, today announced that it has entered into a definitive agreement under which the Company will be acquired by Meda in an all cash transaction. The proposed transaction is subject to customary regulatory approvals and standard closing provisions.

Under the terms of the agreement, Meda will acquire 100% of Acton’s shares for $135 million plus $10 million in a contingent, near-term development milestone. Acton will also receive certain sales-based milestones, which may bring the total potential acquisition value up to $200 million.

Acton is focused on the development of respiratory medicine and recently received U.S. Food and Drug Administration approval for AEROSPAN™ (flunisolide), for the treatment of asthma. AEROSPAN is a HFA-propelled inhaled corticosteroid (ICS) and is the only approved HFA inhaler in its class to incorporate a built-in spacer device, which assists in the delivery of the medicine to the lungs. The value of the U.S. single-entity ICS market is approaching $2 billion with more than 12 million prescriptions written each year.

AEROSPAN Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients 6 years of age and older.

Acton was founded in March 2008 by John Simon, Chief Executive Officer and Daniel Kreisler, President & Chief Operating Officer of Acton.

"Through this transaction with Meda, AEROSPAN will now be commercialized by a company with one of the leading respiratory focused sales forces in the U.S.,” commented Daniel Kreisler. “We strongly believe this will accelerate the prescribing of this unique inhaled steroid product so we can achieve our goal of making AEROSPAN one of the leading therapies in the $2 billion U.S. inhaled steroid market.”

John Simon continued, “We are excited to enter into this agreement with Meda, a leading global pharmaceutical company. Meda’s experience marketing respiratory products combined with their significant track record of success makes them extremely well-suited to launch AEROSPAN to respiratory and pediatric physicians in the U.S.”

Scott Carter, a partner at Sequoia Capital and a member of Acton’s Board of Directors said, “We are very fortunate to partner with Acton Pharmaceuticals. Sequoia Capital recognizes and applauds the excellence of this highly experienced management team who has driven the company to tremendous success.”

Barclays is acting as financial advisor and Bingham McCutchen LLP is acting as legal advisor to Acton in the transaction.

About Sequoia Capital

Since 1972, Sequoia Capital has provided early stage and growth stage venture capital for very smart founders and executives who have turned great ideas into sustainable companies of enduring value. As the "Entrepreneurs Behind the Entrepreneurs", Sequoia Capital's Partners have worked with accomplished innovators and operators who built great franchises such as Ameritox, Amylin Pharmaceuticals, Apple Computer, Cisco Systems, CV Therapeutics, eCardio Diagnostics, Flextronics, Google, Network Appliance, nVidia, Oracle, PayPal, Therasense, Yahoo!, YouTube and Zappos. To learn more about Sequoia Capital visit www.sequoiacap.com/us.

About Acton Pharmaceuticals

Acton is a specialty respiratory pharmaceutical company dedicated to developing prescription drugs to improve the well-being of patients. Acton's corporate headquarters are located in Marlborough, Massachusetts. To learn more about Acton visit, www.actonpharmaceuticals.com.

About Meda AB

Meda AB is leading international specialty pharma company. Meda’s products are sold in more than 120 countries worldwide and the company is represented by its own organizations in over 55 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

AEROSPAN is a trademark of Forest Laboratories, Inc.

Contacts

Acton Pharmaceuticals, Inc.
Daniel L. Kreisler, 508-329-3146
President
dkreisler@actonpharmaceuticals.com
www.actonpharmaceuticals.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->